Fmr LLC Reduces Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

FMR LLC cut its position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 83.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 328,157 shares of the biopharmaceutical company's stock after selling 1,694,443 shares during the period. FMR LLC owned about 0.50% of Regulus Therapeutics worth $515,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of RGLS. Creative Planning bought a new stake in shares of Regulus Therapeutics during the third quarter valued at approximately $26,000. SG Americas Securities LLC bought a new stake in Regulus Therapeutics in the 3rd quarter valued at $33,000. Rhumbline Advisers purchased a new stake in Regulus Therapeutics in the 2nd quarter worth $136,000. Tyche Wealth Partners LLC boosted its holdings in shares of Regulus Therapeutics by 920.6% during the 3rd quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company's stock valued at $167,000 after purchasing an additional 95,694 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Regulus Therapeutics during the 3rd quarter valued at about $204,000. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Regulus Therapeutics in a report on Monday, November 11th. StockNews.com raised Regulus Therapeutics to a "sell" rating in a report on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $10.80.

Regulus Therapeutics Trading Up 2.6 %

Shares of NASDAQ:RGLS traded up $0.04 during trading on Thursday, reaching $1.55. The company's stock had a trading volume of 236,227 shares, compared to its average volume of 1,157,514. The firm's 50 day simple moving average is $1.53 and its two-hundred day simple moving average is $1.70. Regulus Therapeutics Inc. has a 12 month low of $1.08 and a 12 month high of $3.79. The stock has a market capitalization of $101.53 million, a PE ratio of -1.45 and a beta of 1.61.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.